Dr. Justin M. Darrah, MD

Dr. Darrah practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Darrah's NPI, 1487947404, was assigned on May 24, 2011. Dr. Darrah graduated from Lewis Katz School of Medicine in 2011. Dr. Darrah holds California license A135802.

Dr. Darrah's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Darrah's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Darrah practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Darrah's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Darrah's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists chronic anemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Darrah treats.

CMS data shows 713 Medicare services from Dr. Darrah across 9 procedure codes in 2024, for 180 Medicare patients. Medicare paid $65,254 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 180 Medicare patients who saw Dr. Darrah in 2024. The largest group is 65 to 74, with 83 patients. 74% of them have high blood pressure, and 74% have high cholesterol. 36% are also on Medicaid. Their average risk score is 3.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Darrah's median patient age at 66, with 45% women.

In 2024, Dr. Darrah wrote 646 Medicare Part D claims for 91 patients. 86% of them were for generic drugs. CMS names the drug for 453 of them, across 11 drugs with 11 or more claims each, at $576,124 in total drug cost. In 2023, CMS named 421 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Darrah for performance year 2024, reported as part of a group. Dr. Darrah accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Darrah as offering telehealth.

Dmand AI links 6 papers to Dr. Darrah, published from 2009 to 2021. The most frequent topics are Hematopoietic Stem Cell Transplantation. Dr. Darrah's most frequent co-authors are Philippe Armand, MD, PhD, Stephen J. Forman, MD and Alex F. Herrera, MD.

Dmand AI links Dr. Darrah to 9 clinical trials, 2 of them phase 1 studies. 5 are still active or recruiting. Conditions studied include Burkitt Lymphoma, Lymphoma, B-Cell, Marginal Zone and Epstein-Barr Virus Infections. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 85 general payments to Dr. Darrah from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Genmab U.S., Inc. paid the most, $2,326. It also lists 7 research payments totaling $937 in 2018.

Dr. Darrah graduated from Lewis Katz School of Medicine in 2011. Dr. Darrah is a member of AMA, ASCO and ASH.

Dr. Darrah is in network with 14 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.